<DOC>
	<DOC>NCT02149758</DOC>
	<brief_summary>The hypothesis is that Etoricoxib act as an adjuvant to SRP in alleviating periodontal inflammation by: 1. improving clinical periodontal parameters and, 2. improving the salivary SOD levels.</brief_summary>
	<brief_title>EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).</brief_title>
	<detailed_description />
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Superoxide Dismutase</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
	<criteria>Forty patients with chronic generalized periodontitis with system illnesses, allergies, pregnancy, history of any drug intake and periodontal treatment in past 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cyclooxygenase two inhibitors</keyword>
	<keyword>Etoricoxib</keyword>
	<keyword>Periodontitis</keyword>
	<keyword>Superoxide dismutase</keyword>
	<keyword>Saliva</keyword>
</DOC>